ANVS · Annovis Bio Inc
-
-
| Industry | Biotechnology |
|---|---|
| Sector | Healthcare |
| Exchange | NYSE |
| CurrencyCode | USD |
| ISIN | US03615A1088 |
| Beta | 1.51 |
|---|---|
| PE Ratio | None |
| Target Price | 31.2 |
| Market Cap | 31M |
| Dividend Yield | None |
ABOUT
Annovis Bio Inc
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer's disease and dementia. The company was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Learn More